Skip to main content
  • HHS SAMHSA final rule makes PHE opioid-related telehealth flexibilities permanent


    On February 2, 2024, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), published a final rule that expands on, and makes permanent, certain opioid-related telehealth flexibilities initiated during the COVID-19 pandemic. Under the rule, authorized providers will be able to start patients on buprenorphine or methadone—medications used to treat opioid use disorders—pursuant to a telehealth visit and without needing an in-person visit.

    Read more »

By using this site, you agree to the Privacy Policy and acknowledge the use of cookies to store information, which may be essential to making our site work properly or enhancing user experience.